Core Viewpoint - Alto Neuroscience, Inc. (ANRO) has received a Zacks Rank 2 (Buy) upgrade, indicating a positive outlook on its earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Revisions - The Zacks Consensus Estimate for Alto Neuroscience for the fiscal year ending December 2024 is projected at -$2.54 per share, reflecting a 73.9% change from the previous year's reported figure [8]. - Over the past three months, analysts have raised their earnings estimates for Alto Neuroscience by 12.8% [8]. Impact of Institutional Investors - Changes in earnings estimates are strongly correlated with stock price movements, largely due to institutional investors who adjust their valuations based on these estimates [4]. - An increase in earnings estimates typically leads to higher fair value calculations for stocks, prompting institutional buying or selling actions that affect stock prices [4]. Zacks Rating System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 (Strong Buy) stocks historically generating an average annual return of +25% since 1988 [7]. - The upgrade of Alto Neuroscience to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating strong potential for near-term price appreciation [10].
All You Need to Know About Alto Neuroscience, Inc. (ANRO) Rating Upgrade to Buy